New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3

Description

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Preeti Joshi

Dr Preeti Joshi

Cow’s Milk Allergy in Infants and Children

A/Prof Michael Woodward AM

A/Prof Michael Woodward AM

Arexvy is on the NIP – What You Need to Know

A/Prof Li-Chuen Wong

A/Prof Li-Chuen Wong

Eczema Practical Updates for General Practice

Clinical A/Prof Greg Katsoulotos

Clinical A/Prof Greg Katsoulotos

Inhaler Devices Workshop

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Paul Van Buynder

expert

Prof Paul Van Buynder

Public Health Physician and Infectious Diseases Epidemiologist; Professor, School of Medicine, Griffith University, Queensland

Date published: 25 July 2023